Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Newman-Tancredi A, Kleven MS.

Psychopharmacology (Berl). 2011 Aug;216(4):451-73. doi: 10.1007/s00213-011-2247-y. Epub 2011 Mar 11. Review.

PMID:
21394633
2.

The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.

Newman-Tancredi A.

Curr Opin Investig Drugs. 2010 Jul;11(7):802-12. Review.

PMID:
20571976
3.

Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.

Schreiber R, Newman-Tancredi A.

Neurobiol Learn Mem. 2014 Apr;110:72-80. doi: 10.1016/j.nlm.2013.12.015. Epub 2014 Jan 11. Review.

PMID:
24423786
4.

[Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent].

Ohno Y.

Nihon Yakurigaku Zasshi. 2000 Oct;116(4):225-31. Review. Japanese.

PMID:
11084919
5.
6.

The role of serotonin receptors in the action of atypical antipsychotic drugs.

Meltzer HY, Massey BW.

Curr Opin Pharmacol. 2011 Feb;11(1):59-67. doi: 10.1016/j.coph.2011.02.007. Epub 2011 Mar 21. Review.

PMID:
21420906
7.

Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.

Ohno Y, Ishida-Tokuda K, Ishibashi T, Sakamoto H, Tagashira R, Horisawa T, Yabuuti K, Matsumoto K, Kawabe A, Nakamura M.

Pol J Pharmacol. 1997 Aug;49(4):213-9. Review.

PMID:
9437764
8.

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Meltzer HY, Huang M.

Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Review.

PMID:
18772033
9.

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

Millan MJ.

J Pharmacol Exp Ther. 2000 Dec;295(3):853-61. Review.

10.

Receptor mechanisms in the treatment of schizophrenia.

Reynolds GP.

J Psychopharmacol. 2004 Sep;18(3):340-5. Review.

PMID:
15358977
11.

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Ohno Y.

CNS Neurosci Ther. 2011 Feb;17(1):58-65. doi: 10.1111/j.1755-5949.2010.00211.x. Epub 2010 Nov 21. Review.

PMID:
21091640
12.

Mechanism of new antipsychotic medications: occupancy is not just antagonism.

Grunder G, Carlsson A, Wong DF.

Arch Gen Psychiatry. 2003 Oct;60(10):974-7. Review.

PMID:
14557141
13.

Serotonin receptors: their key role in drugs to treat schizophrenia.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Review.

PMID:
14642974
14.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
15.

Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.

Newman-Tancredi A, Cussac D, Depoortere R.

Curr Opin Investig Drugs. 2007 Jul;8(7):539-54. Review.

PMID:
17659474
16.

[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].

Tadori Y, Kikuchi T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Review. Japanese.

PMID:
22568121
17.
18.

Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C.

CNS Drugs. 2006;20(5):389-409. Review.

PMID:
16696579
19.

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

Keck PE Jr, McElroy SL.

Expert Opin Investig Drugs. 2003 Apr;12(4):655-62. Review.

PMID:
12665420
20.

New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy.

Urs NM, Peterson SM, Caron MG.

Biol Psychiatry. 2017 Jan 1;81(1):78-85. doi: 10.1016/j.biopsych.2016.10.011. Epub 2016 Oct 19. Review.

Supplemental Content

Support Center